Elevation of plasma milrinone concentrations in stage D heart failure associated with renal dysfunction

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 18, Issue 5, 2013, Pages 433-438

  Cox, Zachary L ^a,b   Calcutt, Marion W ^b   Morrison, Thomas B ^c   Akers, Wendell S ^a   Davis, Mary Beth ^c   Lenihan, Daniel J ^c  

^a LIPSCOMB UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cardiology; heart failure; milrinone; pharmacokinetics; renal dysfunction

Indexed keywords

CREATININE; MILRINONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; FEMALE; HEART CATHETERIZATION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART HEMODYNAMICS; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INFUSION RATE; KIDNEY DYSFUNCTION; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEADY STATE;

ADULT; AGED; CARDIAC CATHETERIZATION; CARDIOTONIC AGENTS; CREATININE; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; MILRINONE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TACHYCARDIA, VENTRICULAR;

EID: 84882238136     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413489773     Document Type: Article

References (33)

1. Ahmad T, Patel CB, Milano CA, Rogers JG. When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure. Circulation. 2012 ; 125 (23). 2948-2955
2. Young JB, Moen EK. Outpatient parenteral inotropic therapy for advanced heart failure. J Heart Lung Transplant. 2000 ; 19 (suppl 8). S49 - S57
3. Cusick DA, Pfeifer PB, Quigg RJ. Effects of intravenous milrinone followed by titration of high-dose oral vasodilator therapy on clinical outcome and rehospitalization rates in patients with severe heart failure. Am J Cardiol. 1998 ; 82 (9). 1060-1065
4. Canver CC, Chanda J. Milrinone for long-term pharmacologic support of the status 1 heart transplant candidates. Ann Thorac Surg. 2000 ; 69 (6). 1823-1826
5. Mehra MR, Ventura HO, Kapoor C, Stapleton DD, Zimmerman D, Smart FW. Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. Am J Cardiol. 1997 ; 80 (1). 61-64
6. Upadya S, Lee FA, Saldarriaga C, et al. Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. J Heart Lung Transplant. 2004 ; 23 (4). 466-472
7. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy. Circulation. 2003 ; 108 (4). 492-497
8. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the acute decompensated heart failure national registry (ADHERE). J Am Coll Cardiol. 2005 ; 46 (1). 57-64
9. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: inotropic infusions during hospitalization. Circulation. 2003 ; 108 (3). 367-372
10. Eatontown, NJ, USA: ; 2010:
11. Bailey JM, Levy JH, Kikura M, Szlam F, Hug CC. Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. Anesthesiology. 1994 ; 81 (3). 616-622
12. Larsson R, Liedholm H, Andersson KE, Keane MA, Henry G. Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment. Eur J Clin Pharmacol. 1986 ; 29 (5). 549-553
13. Woolfrey SG, Hegbrant J, Thysell H, et al. Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure. J Pharm Pharmacol. 1995 ; 47 (8). 651-655
14. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001 ; 345 (20). 1435-1443
15. Rogers JG, Butler J, Lansman SL, et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol. 2007 ; 50 (8). 741-747
16. Ferrick KJ, Fein SA, Ferrick AM, Doyle JT. Effect of milrinone on ventricular arrhythmias in congestive heart failure. Am J Cardiol. 1990 ; 66 (4). 431-434
17. Holmes JR, Kubo SH, Cody RJ, Kligfield P. Milrinone in congestive heart failure: observations on ambulatory ventricular arrhythmias. Am Heart J. 1985 ; 110 (4). 800-806
18. Anderson JL, Askins JC, Gilbert EM, Menlove RL, Lutz JR. Occurrence of ventricular arrhythmias in patients receiving acute and chronic infusions of milrinone. Am Heart J. 1986 ; 111 (3). 466-474
19. Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis. 1995 ; 38 (2). 167-180
20. Cuffe MS, Califf RM, Adams KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002 ; 287 (12). 1541-1547
21. Hasei M, Uchiyama A, Nishimura M, Mashimo T, Fujino Y. Correlation between plasma milrinone concentration and renal function in patients with cardiac disease. Acta Anaesthesiol Scand. 2008 ; 52 (7). 991-996
22. Taniguchi T, Shibata K, Saito S, Matsumoto H, Okeie K. Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration. Intensive Care Med. 2000 ; 26 (8). 1089-1093
23. Edelson J, Stroshane R, Benziger DP, et al. Pharmacokinetics of bipyridines amrinone and milrinone. Circulation. 1986 ; 73 (3 pt 2). III145 - III149
24. Hasei M, Uchiyama A, Iguchi N, et al. A case of continuous infusion of milrinone during continuous venovenous hemofiltration causing high plasma concentration of milrinone. Masui. 2005 ; 54 (2). 180-182
25. Kikura M, Levy JH, Michelsen LG, et al. The effect of milrinone on hemodynamics and left ventricular function after emergence from cardiopulmonary bypass. Anesth Analg. 1997 ; 85 (1). 16-22
26. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation. 1986 ; 74 (6). 1290-1302
27. Böhm M, Diet F, Feiler G, et al. Subsensitivity of the failing human heart to isoprenaline and milrinone is related to beta-adrenoceptor downregulation. J Cardiovasc Pharmacol. 1988 ; 12 (6). 726-732
28. Böhm M, Gierschik P, Jakobs KH, et al. Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy. Circulation. 1990 ; 82 (4). 1249-1265
29. Packer M, Carver JR, Rodeheffer RJ. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group. N Engl J Med. 1991 ; 325 (21). 1468-1475
30. Teerlink JR. A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev. 2009 ; 14 (4). 289-298
31. Shah SJ, Wasserstrom JA. SERCA2a gene therapy for the prevention of sudden cardiac death: a future "theranostic" for heart failure?. Circulation. 2012 ; 126 (17). 2047-2050
32. Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 2010 ; 21 (9). 1550-1559
33. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003 ; 289 (7). 871-878